PMID- 36220865
OWN - NLM
STAT- MEDLINE
DCOM- 20221013
LR  - 20231103
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Oct 11
TI  - Deterioration of liver function and aging disturb sequential systemic therapy for 
      unresectable hepatocellular carcinoma.
PG  - 17018
LID - 10.1038/s41598-022-21528-2 [doi]
LID - 17018
AB  - This study aimed to investigate the clinical characteristics of patients with 
      unresectable hepatocellular carcinoma (HCC), who were eligible for sequential 
      systemic therapy. We evaluated 365 patients with HCC who underwent systemic 
      therapy after 2017. The overall survival (OS) was 13.7 months, 19.2 months, and 
      35.6 months in the first-line, second-line, and third-line or later therapy 
      groups, respectively. Multivariate analysis revealed that the 
      modified-albumin-bilirubin (m-ALBI) grade, macrovascular invasion, extrahepatic 
      spread, discontinuation due to adverse events (AEs), and sequential therapy were 
      independent factors for OS. At the end of each therapy, the ALBI score was 
      significantly worse among patients with discontinuation due to AEs than among 
      those without. The conversion rate to second-line and third-line therapy among 
      patients with discontinuation due to AEs was significantly lower than that among 
      patients without (30.4% vs. 69.2%, p < 0.001; 6.7% vs. 58.3%; p < 0.001, 
      respectively). In the decision tree analysis, m-ALBI grade 1 or 2a and 
      non-advanced age were selected splitting variables, respectively, for sequential 
      systemic therapy. In conclusion, sequential therapy prolonged the OS of 
      unresectable HCC. Additionally, good hepatic function and non-advanced age were 
      clinically eligible characteristics for sequential systemic therapy.
CI  - (c) 2022. The Author(s).
FAU - Shimose, Shigeo
AU  - Shimose S
AUID- ORCID: 0000-0003-2068-8386
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan. 
      shimose_shigeo@med.kurume-u.ac.jp.
FAU - Hiraoka, Atsushi
AU  - Hiraoka A
AD  - Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, 790-0024, 
      Japan.
FAU - Tanaka, Masatoshi
AU  - Tanaka M
AD  - Clinical Research Center, Yokokura Hospital, Miyama, Fukuoka, 839-0295, Japan.
FAU - Iwamoto, Hideki
AU  - Iwamoto H
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
AD  - Iwamoto Internal Medical Clinic, Kitakyusyu, 802-0832, Japan.
FAU - Tanaka, Takaaki
AU  - Tanaka T
AD  - Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, 790-0024, 
      Japan.
FAU - Noguchi, Kazunori
AU  - Noguchi K
AD  - Department of Gastroenterology, Omuta City Hospital, Omuta, 836-0861, Japan.
FAU - Aino, Hajime
AU  - Aino H
AD  - Division of Gastroenterology, Department of Medicine, Social Insurance Tagawa 
      Hospital, Tagawa, 826-0023, Japan.
FAU - Yamaguchi, Taizo
AU  - Yamaguchi T
AD  - Iwamoto Internal Medical Clinic, Kitakyusyu, 802-0832, Japan.
FAU - Itano, Satoshi
AU  - Itano S
AD  - Department of Gastroenterology, Kurume Central Hospital, Kurume, 830-0001, Japan.
FAU - Suga, Hideya
AU  - Suga H
AD  - Department of Gastroenterology and Hepatology, Yanagawa Hospital, Yanagawa, 
      832-0077, Japan.
FAU - Niizeki, Takashi
AU  - Niizeki T
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
FAU - Moriyama, Etsuko
AU  - Moriyama E
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
FAU - Shirono, Tomotake
AU  - Shirono T
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
FAU - Noda, Yu
AU  - Noda Y
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
FAU - Kamachi, Naoki
AU  - Kamachi N
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
FAU - Okamura, Shusuke
AU  - Okamura S
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
FAU - Nakano, Masahito
AU  - Nakano M
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
FAU - Kawaguchi, Takumi
AU  - Kawaguchi T
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
FAU - Kuromatsu, Ryoko
AU  - Kuromatsu R
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
FAU - Koga, Hironori
AU  - Koga H
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
FAU - Torimura, Takuji
AU  - Torimura T
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of 
      Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
LA  - eng
PT  - Journal Article
DEP - 20221011
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Serum Albumin)
RN  - RFM9X3LJ49 (Bilirubin)
SB  - IM
MH  - Aging
MH  - Bilirubin
MH  - *Carcinoma, Hepatocellular/pathology
MH  - Humans
MH  - *Liver Neoplasms/pathology
MH  - Retrospective Studies
MH  - Serum Albumin
PMC - PMC9554046
COIS- Atsushi Hiraoka received honoraria (lecture fees) from Bayer, Eisai, Eli Lilly, 
      and Otsuka Pharmaceutical. Takumi Kawaguchi received honoraria (lecture fees) 
      from Mitsubishi Tanabe Pharma Corporation and Otsuka Pharmaceutical Co., Ltd. The 
      other authors declare no conflicts of interest.
EDAT- 2022/10/12 06:00
MHDA- 2022/10/14 06:00
PMCR- 2022/10/11
CRDT- 2022/10/11 23:22
PHST- 2022/07/05 00:00 [received]
PHST- 2022/09/28 00:00 [accepted]
PHST- 2022/10/11 23:22 [entrez]
PHST- 2022/10/12 06:00 [pubmed]
PHST- 2022/10/14 06:00 [medline]
PHST- 2022/10/11 00:00 [pmc-release]
AID - 10.1038/s41598-022-21528-2 [pii]
AID - 21528 [pii]
AID - 10.1038/s41598-022-21528-2 [doi]
PST - epublish
SO  - Sci Rep. 2022 Oct 11;12(1):17018. doi: 10.1038/s41598-022-21528-2.